May 13, 2021
Business News

Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update

HENDERSON, Nev.–()–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2020.

“The Fast Track designation for poziotinib is a significant achievement towards an expedited review,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “In addition, we are delighted that the FDA has scheduled the pre-approval inspection at the ROLONTIS manufacturing facility for May 2021. The company has made tremendous progress advancing our development programs and conducting our clinical trials, despite the challenges of the global pandemic. I…

Click here to view the original article.

Related Posts

You might also like ...

Advanced Drainage Systems Recognized for Product and Environmental Sustainability Leadership at Columbus Metropolitan Club Forum
Guardicore Recognized as an Inc. Magazine Best Workplace for 2021
Samenvatting: Gegevens uit de oncologieportfolio van Incyte geaccepteerd voor presentatie op het virtuele EHA-congres in 2021